Brokerages predict that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will report ($0.67) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Zynerba Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.73). Zynerba Pharmaceuticals reported earnings per share of ($0.60) in the same quarter last year, which would suggest a negative year-over-year growth rate of 11.7%. The firm is scheduled to announce its next earnings report on Monday, March 11th.
On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.87) per share for the current financial year, with EPS estimates ranging from ($2.94) to ($2.79). For the next year, analysts forecast that the company will post earnings of ($2.43) per share, with EPS estimates ranging from ($2.77) to ($1.84). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.23.
Several equities research analysts recently commented on the stock. Cantor Fitzgerald set a $21.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. HC Wainwright set a $23.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 13th. Finally, Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a research note on Saturday, November 17th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.75.
Several hedge funds and other institutional investors have recently modified their holdings of ZYNE. Millennium Management LLC bought a new position in shares of Zynerba Pharmaceuticals in the first quarter worth approximately $903,000. Alps Advisors Inc. lifted its stake in shares of Zynerba Pharmaceuticals by 41.3% in the second quarter. Alps Advisors Inc. now owns 51,375 shares of the company’s stock worth $504,000 after buying an additional 15,019 shares in the last quarter. LMR Partners LLP bought a new position in shares of Zynerba Pharmaceuticals in the second quarter worth approximately $312,000. Engineers Gate Manager LP purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $231,000. Finally, Raymond James & Associates purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $164,000. Hedge funds and other institutional investors own 16.50% of the company’s stock.
NASDAQ:ZYNE traded down $0.22 during mid-day trading on Monday, hitting $4.69. 2,520 shares of the company’s stock were exchanged, compared to its average volume of 266,310. Zynerba Pharmaceuticals has a one year low of $4.50 and a one year high of $14.45. The firm has a market capitalization of $86.55 million, a P/E ratio of -1.87 and a beta of 4.46.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Featured Story: How does a reverse stock split work?
Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.